FCGR3A and neoplasm: and Snyder et al., which observed that the high-affinity FcγRIIIa-V158F polymorphism was associated with improved RR in patients with advanced melanoma treated with ipilimumab, but only in the context of high putative neoantigen or indel burden [tumour-specific indel (insertion or deletion) mutations], respectively (pmeta=0.043 and pmeta=0.016, respectively) (35, 36).